Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer
Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer
复制标题
DOI：
10.1159/000096002
复制
发表时间：
2006-01-01
期刊：
影响因子：
3.3
通讯作者：
Miyagawa, Shinichi
中科院分区：
文献类型：
--
作者：
Ishizone, Satoshi;Maruta, Fukuto;Miyagawa, Shinichi
背景：本研究旨在观察替吉奥治疗胃癌腹膜转移患者的疗效和依从性。方法：连续16例胃癌腹膜转移患者接受替吉奥治疗。将其生存率与历史对照组（25例患者）进行比较。检测胸苷酸合成酶、二氢嘧啶脱氢酶、胸苷磷酸化酶和乳清酸磷酸核糖转移酶mRNA在肿瘤中的表达。结果如下：S-1治疗患者的中位生存期为550天，显著长于历史对照组（215天）。我们阐明了S-1治疗腹膜转移患者延长生存期的一些因素：腹膜转移无其他远处转移，S-1治疗与胃切除术的联合，以及原发肿瘤中胸苷磷酸化酶mRNA的低表达。结论：S-1治疗胃癌腹膜转移有较好的远期疗效，且毒副作用小。版权所有（c）2006 S. Karger AG，巴塞尔。
Background: This study was designed to examine the efficacy and compliance of S-1 for the patients with peritoneal metastasis of gastric cancer. Methods: Sixteen consecutive patients with peritoneal metastasis of gastric cancer were treated with S-1. Their survival was compared with that of the historical control group (25 patients). Thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase and orotate phosphoribosyl transferase mRNA expression in the tumor were evaluated. Results: The median survival time of S-1-treated patients was 550 days, which was significantly longer than that of the historical control group (215 days). We elucidated some factors to prolong the survival of the patients treated with S-1 for peritoneal metastasis: peritoneal metastasis without other distant metastases, the combination of S-1 treatment and gastrectomy, and low expression of thymidine phosphorylase mRNA in primary tumors. Conclusions: S-1 showed a surprisingly long-term survival with minimum toxicity in patients with peritoneal metastasis of gastric cancer. Copyright (c) 2006 S. Karger AG, Basel.